Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thorsten Simon

Showing results (121-130 of 124) with videos related to

Pageof 13
Sort By:
You have reached the last page of results.This site can display upto 124 results.
Science (New York, N.Y.)|December 8, 2018
A mechanistic classification of clinical phenotypes in neuroblastomaSandra Ackermann, Maria Cartolano, Barbara Hero, et al.
The Journal of Clinical Investigation|February 12, 2026
Mutated FGFR1 is an oncogenic driver and therapeutic target in high-risk neuroblastomaLisa Werr, Jana Boland, Josephine Petersen, et al.
The Lancet. Oncology|June 27, 2024
Irinotecan and temozolomide in combination with dasatinib and rapamycin versus irinotecan and temozolomide for patients with relapsed or refractory neuroblastoma (RIST-rNB-2011): a multicentre, open-label, randomised, controlled, phase 2 trialSelim Corbacioglu, Holger Lode, Susanne Ellinger, et al.
American Journal of Medical Genetics. Part A|February 8, 2017
Childhood cancer predisposition syndromes-A concise review and recommendations by the Cancer Predisposition Working Group of the Society for Pediatric Oncology and HematologyTim Ripperger, Stefan S Bielack, Arndt Borkhardt, et al.
Pageof 13

Showing results (121-130 of 124) with videos related to

Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 124 results.
Science (New York, N.Y.)|December 8, 2018
A mechanistic classification of clinical phenotypes in neuroblastomaSandra Ackermann, Maria Cartolano, Barbara Hero, et al.
The Journal of Clinical Investigation|February 12, 2026
Mutated FGFR1 is an oncogenic driver and therapeutic target in high-risk neuroblastomaLisa Werr, Jana Boland, Josephine Petersen, et al.
The Lancet. Oncology|June 27, 2024
Irinotecan and temozolomide in combination with dasatinib and rapamycin versus irinotecan and temozolomide for patients with relapsed or refractory neuroblastoma (RIST-rNB-2011): a multicentre, open-label, randomised, controlled, phase 2 trialSelim Corbacioglu, Holger Lode, Susanne Ellinger, et al.
American Journal of Medical Genetics. Part A|February 8, 2017
Childhood cancer predisposition syndromes-A concise review and recommendations by the Cancer Predisposition Working Group of the Society for Pediatric Oncology and HematologyTim Ripperger, Stefan S Bielack, Arndt Borkhardt, et al.
Pageof 13